MeiraGTx
Manufacturing · New York, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
450 E 29th St Fl 14, New York City, New ...Phone Number
(646) 860-7985Website
www.meiragtx.comRevenue
$79.8 MillionStock Symbol
MGTXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About MeiraGTx
MeiraGTx is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs.Explore more
MeiraGTx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MeiraGTx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on MeiraGTx recently announced quarterly report
Product Launch: Get notified when MeiraGTx launches new products
Click to see if MeiraGTx had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at MeiraGTx
Competitive Alert! Recent activity has been detected by your competitor Masked Content
MeiraGTx, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once MeiraGTx has new funding data
Check out if MeiraGTx is spiking on competitors!
Check if MeiraGTx has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at MeiraGTx
Find 3 more new buyers
Compare Similar Companies to MeiraGTx
Compare insights from companies similar to MeiraGTx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
MeiraGTx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MeiraGTx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MeiraGTx.
MeiraGTx financials insights
Gather financial insights about MeiraGTx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Debt
$100M
MeiraGTx Tech Stack
A closer look at the technologies used by MeiraGTx
See more technologies
Most Recent Scoops
Project
MeiraGTx has entered into an arrangement with Sanofi, under which Sanofi holds rights of first refusal (ROFRs) on MeiraGTx's RiboSwitch and xerostomia programs, granting Sanofi a defined review window to evaluate program data before it is shared with other parties.
Project
MeiraGTx has confirmed full FDA alignment on both chemistry, manufacturing, and controls (CMC) and clinical design for its radiation-induced xerostomia program to support a BLA filing, and is exploring plans to self-commercialize the therapy in the US while pursuing priority review given its RMAT and Breakthrough designations.
Pharmaceuticals, Clinical Operations
Project
MeiraGTx is conducting a pivotal study for its wholly owned radiation-induced xerostomia program, which holds Breakthrough and RMAT designations, with 12-month data expected in approximately one year and a BLA filing targeting potential approval at the end of 2027 and a commercial launch in early 2028.
Pharmaceuticals, Clinical Operations
Project
MeiraGTx has completed enrollment for its pivotal Phase II study in radiation-induced xerostomia, supported by Phase I data demonstrating durable efficacy results maintained from 12 months through three years of follow-up.
Medical Research, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
MeiraGTx News & Media
MeiraGTx Holdings plc (MGTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
MeiraGTx Holdings plc (MGTX) Jefferies Global Healthcare Conference 2026 June 4, 2026 3:10 PM EDTCompany ParticipantsAlexandria Forbes - CEO, President...Can MeiraGTx Holdings PLC (MGTX) Stock Double? Cash Runway Offers a Hint
MeiraGTx Holdings PLC (NASDAQ:MGTX) is one of the best gene therapy stocks to buy in 2026. The stock has gained around 25% year-to-date and soared more than 95% over the past year. Looking ahead, analysts believe the stock could explode more than 100% in the next 12 months as MeiraGTx advances its various therapy programs. […]MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company’s Board of Directors approved equity awards to Penny Fleck in connection with her employment with the Company as Chief Development Officer. The equity awards were granted as an inducement material to the new employee entering employment with MeiraGTx in accordance with Nasdaq LMeiraGTx Reports First Quarter 2026 Financial and Operational Results
LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the first quarter ended March 31, 2026, and provided a corporate update.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding MeiraGTx
Sign Up For FreeTo access detailed company insights
MeiraGTx is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs.... Read More
